These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 23049204)
1. Pancreatic ductal adenocarcinoma screening: new perspectives. Pezzilli R; Fabbri D; Imbrogno A World J Gastroenterol; 2012 Sep; 18(36):4973-7. PubMed ID: 23049204 [TBL] [Abstract][Full Text] [Related]
2. Potential biomarkers for early detection of pancreatic ductal adenocarcinoma. Kriz D; Ansari D; Andersson R Clin Transl Oncol; 2020 Dec; 22(12):2170-2174. PubMed ID: 32447642 [TBL] [Abstract][Full Text] [Related]
3. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma. Yu J; Ploner A; Kordes M; Löhr M; Nilsson M; de Maturana MEL; Estudillo L; Renz H; Carrato A; Molero X; Real FX; Malats N; Ye W Int J Cancer; 2021 Apr; 148(8):2048-2058. PubMed ID: 33411965 [TBL] [Abstract][Full Text] [Related]
4. PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma. Gold DV; Gaedcke J; Ghadimi BM; Goggins M; Hruban RH; Liu M; Newsome G; Goldenberg DM Cancer; 2013 Feb; 119(3):522-8. PubMed ID: 22898932 [TBL] [Abstract][Full Text] [Related]
8. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study. Distler M; Pilarsky E; Kersting S; Grützmann R Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419 [TBL] [Abstract][Full Text] [Related]
9. Early detection and imaging strategies to reveal and target developing pancreatic cancer. Crawford HC; Wallace MB; Storz P Expert Rev Anticancer Ther; 2020 Feb; 20(2):81-83. PubMed ID: 31986932 [No Abstract] [Full Text] [Related]
10. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part II, update on imaging techniques and screening of pancreatic cancer in high-risk individuals. Kulkarni NM; Mannelli L; Zins M; Bhosale PR; Arif-Tiwari H; Brook OR; Hecht EM; Kastrinos F; Wang ZJ; Soloff EV; Tolat PP; Sangster G; Fleming J; Tamm EP; Kambadakone AR Abdom Radiol (NY); 2020 Mar; 45(3):729-742. PubMed ID: 31768594 [TBL] [Abstract][Full Text] [Related]
11. [Prognostic factors for long-term survival in patients with pancreatic ductal adenocarcinoma]. Kawaida H; Fujii H Nihon Rinsho; 2015 Mar; 73 Suppl 3():181-5. PubMed ID: 25857011 [No Abstract] [Full Text] [Related]
12. Screening for pancreatic cancer: a review for general clinicians. Wiest NE; Moktan VP; Oman SP; Chirilă RM Rom J Intern Med; 2020 Sep; 58(3):119-128. PubMed ID: 32364522 [TBL] [Abstract][Full Text] [Related]
13. Expression and diagnostic evaluation of the human tumor-associated antigen RCAS1 in pancreatic cancer. Akashi T; Oimomi H; Nishiyama K; Nakashima M; Arita Y; Sumii T; Kimura T; Ito T; Nawata H; Watanabe T Pancreas; 2003 Jan; 26(1):49-55. PubMed ID: 12499917 [TBL] [Abstract][Full Text] [Related]
14. Clinical significance of cathepsin E in pancreatic juice in the diagnosis of pancreatic ductal adenocarcinoma. Uno K; Azuma T; Nakajima M; Yasuda K; Hayakumo T; Mukai H; Sakai T; Kawai K J Gastroenterol Hepatol; 2000 Nov; 15(11):1333-8. PubMed ID: 11129230 [TBL] [Abstract][Full Text] [Related]
15. Screening for Pancreatic Ductal Adenocarcinoma: Are We Asking the Impossible? Caldwell KE; Conway AP; Hammill CW Cancer Prev Res (Phila); 2021 Mar; 14(3):373-382. PubMed ID: 33148677 [TBL] [Abstract][Full Text] [Related]
16. Pancreatic Cancer Screening among High-risk Individuals. Turner KM; Patel SH Surg Clin North Am; 2024 Oct; 104(5):951-964. PubMed ID: 39237170 [TBL] [Abstract][Full Text] [Related]
17. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. McGuigan A; Kelly P; Turkington RC; Jones C; Coleman HG; McCain RS World J Gastroenterol; 2018 Nov; 24(43):4846-4861. PubMed ID: 30487695 [TBL] [Abstract][Full Text] [Related]
18. Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer. Joergensen MT; Brünner N; De Muckadell OB Anticancer Res; 2010 Feb; 30(2):587-92. PubMed ID: 20332475 [TBL] [Abstract][Full Text] [Related]
19. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma. Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665 [TBL] [Abstract][Full Text] [Related]
20. Intraductal Papillary Mucinous Neoplasm of the Pancreas as the Main Focus for Early Detection of Pancreatic Adenocarcinoma. Tanaka M Pancreas; 2018; 47(5):544-550. PubMed ID: 29702531 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]